Advertisement

The Evolving Landscape of Neuroendocrine Tumors

Published:November 03, 2022DOI:https://doi.org/10.1016/j.soc.2022.08.003

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Surgical Oncology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Dasari A.
        • Shen D.
        • Halperin B.
        • et al.
        Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the united states.
        JAMA Oncol. 2017; 3: 1335-1342
        • Frilling A.
        • Modlin I.M.
        • Kidd M.
        • et al.
        Recommendations for management of patients with neuroendocrine liver metastases.
        Lancet Oncol. 2014; 15: e8-e21
        • Pavel M.
        • Baudin E.
        • Couvelard A.
        • et al.
        ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary.
        Neuroendocrinology. 2012; 95: 157-176
        • Bilimoria K.Y.
        • Bentrem D.J.
        • Wayne J.D.
        • et al.
        Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years.
        Ann Surg. 2009; 249: 63-71
        • Keck K.J.
        • Maxwell J.E.
        • Utria A.F.
        • et al.
        The distal predilection of small bowel neuroendocrine tumors.
        Ann Surg Oncol. 2018; 25: 3207-3213
        • Kuiper D.H.
        • Gracie Jr., W.A.
        • Pollard H.M.
        Twenty years of gastrointestinal carcinoids.
        Cancer. 1970; 25: 1424-1430
        • Howe J.R.
        • Cardona K.
        • Fraker D.L.
        • et al.
        The surgical management of small bowel neuroendocrine tumors: consensus guidelines of the north american neuroendocrine tumor society.
        Pancreas. 2017; 46: 715-731
        • Niederle B.
        • Pape U.F.
        • Costa F.
        • et al.
        ENETS consensus guidelines update for neuroendocrine neoplasms of the jejunum and ileum.
        Neuroendocrinology. 2016; 103: 125-138
        • Tierney J.F.
        • Chivukula S.V.
        • Wang X.
        • et al.
        Resection of primary tumor may prolong survival in metastatic gastroenteropancreatic neuroendocrine tumors.
        Surgery. 2019; 165: 644-651
        • Mayo S.C.
        • de Jong M.C.
        • Pulitatno C.
        • et al.
        Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis.
        Ann Surg Oncol. 2010; 17: 3129-3136
        • Givi B.
        • Pommier S.J.
        • Thompson A.K.
        • et al.
        Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival.
        Surgery. 2006; 140 ([discussion: 897-8]): 891-897
        • Sarmiento J.M.
        • Heywood G.
        • Rubin J.
        • et al.
        Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival.
        J Am Coll Surg. 2003; 197: 29-37
        • Chambers A.J.
        • Pasieka J.L.
        • Dixon E.
        • et al.
        The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors.
        Surgery. 2008; 144 ([discussion: 651-3]): 645-651
        • Bennett S.
        • Coburn N.
        • Law C.
        • et al.
        Upfront small bowel resection for small bowel neuroendocrine tumors with synchronous metastases: a propensity-score matched comparative population-based analysis.
        Ann Surg. 2020; (Online ahead of print)
        • Gangi A.
        • Manguso N.
        • Gong J.
        • et al.
        Midgut neuroendocrine tumors with liver-only metastases: benefit of primary tumor resection.
        Ann Surg Oncol. 2020; 27: 4525-4532
        • Ahmed A.
        • Turner G.
        • King B.
        • et al.
        Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study.
        Endocr Relat Cancer. 2009; 16: 885-894
        • Wang S.C.
        • Parekh J.R.
        • Zuraek M.B.
        • et al.
        Identification of unknown primary tumors in patients with neuroendocrine liver metastases.
        Arch Surg. 2010; 145: 276-280
        • Kasai Y.
        • Mahuron K.
        • Hirose K.
        • et al.
        A novel stratification of mesenteric mass involvement as a predictor of challenging mesenteric lymph node dissection by minimally invasive approach for ileal neuroendocrine tumors.
        J Surg Oncol. 2020; 122: 204-211
        • Ohrvall U.
        • Eriksson B.
        • Juhlin C.
        • et al.
        Method for dissection of mesenteric metastases in mid-gut carcinoid tumors.
        World J Surg. 2000; 24: 1402-1408
        • Tran C.G.
        • Sherman S.K.
        • Howe J.R.
        Small bowel neuroendocrine tumors.
        Curr Probl Surg. 2020; 57: 100823
        • Landry C.S.
        • Lin H.Y.
        • Phan A.
        • et al.
        Resection of at-risk mesenteric lymph nodes is associated with improved survival in patients with small bowel neuroendocrine tumors.
        World J Surg. 2013; 37: 1695-1700
        • Daskalakis K.
        • Karakatsanis A.
        • Hessman O.
        • et al.
        Association of a prophylactic surgical approach to stage iv small intestinal neuroendocrine tumors with survival.
        JAMA Oncol. 2018; 4: 183-189
        • Hallet J.
        • Law C.
        • Commonwealth S.
        Neuroendocrine tumours research collaborative surgical, role of primary tumor resection for metastatic small bowel neuroendocrine tumors.
        World J Surg. 2021; 45: 213-218
        • Poultsides G.A.
        • Huang L.C.
        • Chen Y.
        • et al.
        Pancreatic neuroendocrine tumors: radiographic calcifications correlate with grade and metastasis.
        Ann Surg Oncol. 2012; 19: 2295-2303
        • Dong D.H.
        • Zhang X.F.
        • Poultisides G.
        • et al.
        Impact of tumor size and nodal status on recurrence of nonfunctional pancreatic neuroendocrine tumors </=2 cm after curative resection: A multi-institutional study of 392 cases.
        J Surg Oncol. 2019; 120: 1071-1079
        • Cherenfant J.
        • Stocker S.J.
        • Gage M.K.
        • et al.
        Predicting aggressive behavior in nonfunctioning pancreatic neuroendocrine tumors.
        Surgery. 2013; 154 ([discussion: 791-3]): 785-791
        • Sadot E.
        • Reidy-Lagunes L.
        • Tang L.H.
        • et al.
        Observation versus resection for small asymptomatic pancreatic neuroendocrine tumors: a matched case-control study.
        Ann Surg Oncol. 2016; 23: 1361-1370
        • Gaujoux S.
        • Partelli S.
        • Maire F.
        • et al.
        Observational study of natural history of small sporadic nonfunctioning pancreatic neuroendocrine tumors.
        J Clin Endocrinol Metab. 2013; 98: 4784-4789
        • Lee L.C.
        • Grant C.S.
        • Salomao D.R.
        • et al.
        Small, nonfunctioning, asymptomatic pancreatic neuroendocrine tumors (PNETs): role for nonoperative management.
        Surgery. 2012; 152: 965-974
        • Kurita Y.
        • Hara K.
        • Kuwahara T.
        • et al.
        Comparison of prognosis between observation and surgical resection groups with small sporadic non-functional pancreatic neuroendocrine neoplasms without distant metastasis.
        J Gastroenterol. 2020; 55: 543-552
        • Barenboim A.
        • Lahat G.
        • Nachmany I.
        • et al.
        Resection versus observation of small asymptomatic nonfunctioning pancreatic neuroendocrine tumors.
        J Gastrointest Surg. 2020; 24: 1366-1374
        • Rosenberg A.M.
        • Friedmann P.
        • Del Rivero J.
        • et al.
        Resection versus expectant management of small incidentally discovered nonfunctional pancreatic neuroendocrine tumors.
        Surgery. 2016; 159: 302-309
        • Regenet N.
        • Carrere N.
        • Boulanger G.
        • et al.
        Is the 2-cm size cutoff relevant for small nonfunctioning pancreatic neuroendocrine tumors: a French multicenter study.
        Surgery. 2016; 159: 901-907
        • Zaidi M.Y.
        • Lopez-Aguiar A.G.
        • Switchenko J.M.
        • et al.
        A novel validated recurrence risk score to guide a pragmatic surveillance strategy after resection of pancreatic neuroendocrine tumors: an international study of 1006 patients.
        Ann Surg. 2019; 270: 422-433
        • Howe J.R.
        • Merchant N.B.
        • Conrad C.
        • et al.
        The north american neuroendocrine tumor society consensus paper on the surgical management of pancreatic neuroendocrine tumors.
        Pancreas. 2020; 49: 1-33
        • Falconi M.
        • Erikkson B.
        • Kaltsas G.
        • et al.
        ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors.
        Neuroendocrinology. 2016; 103: 153-171
        • Falconi M.
        • Bartsch D.K.
        • Erikkson B.
        • et al.
        ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors.
        Neuroendocrinology. 2012; 95: 120-134
        • Mansour J.C.
        • Chavin K.
        • Morris-Stiff G.
        • et al.
        Management of asymptomatic, well-differentiated PNETs: results of the Delphi consensus process of the Americas Hepato-Pancreato-Biliary Association.
        HPB (Oxford). 2019; 21: 515-523
      1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Guideline Name V.X.202X. © National Comprehensive Cancer Network, Inc. 202X. NCCN.org. Accessed April 1, 2022.

        • Tanaka M.
        • Heckler M.
        • Mihaljevic A.L.
        • et al.
        Systematic review and metaanalysis of lymph node metastases of resected pancreatic neuroendocrine tumors.
        Ann Surg Oncol. 2021; 28: 1614-1624
        • Mao R.
        • Zhao H.
        • Li K.
        • et al.
        Outcomes of lymph node dissection for non-metastatic pancreatic neuroendocrine tumors: a propensity score-weighted analysis of the National Cancer Database.
        Ann Surg Oncol. 2019; 26: 2722-2729
        • Conrad C.
        • Kutlu O.C.
        • Dasari A.
        • et al.
        Prognostic value of lymph node status and extent of lymphadenectomy in pancreatic neuroendocrine tumors confined to and extending beyond the pancreas.
        J Gastrointest Surg. 2016; 20: 1966-1974
        • Lopez-Aguiar A.G.
        • Ethun C.G.
        • Zaidi M.Y.
        • et al.
        The conundrum of < 2-cm pancreatic neuroendocrine tumors: a preoperative risk score to predict lymph node metastases and guide surgical management.
        Surgery. 2019; 166: 15-21
        • Mehrabi A.
        • Fischer L.
        • Hafezi M.
        • et al.
        A systematic review of localization, surgical treatment options, and outcome of insulinoma.
        Pancreas. 2014; 43: 675-686
        • Partelli S.
        • Cirocchi R.
        • Crippa S.
        • et al.
        Systematic review of active surveillance versus surgical management of asymptomatic small non-functioning pancreatic neuroendocrine neoplasms.
        Br J Surg. 2017; 104: 34-41
        • Sadowski S.M.
        • Pieterman C.R.C.
        • Perrier N.D.
        • et al.
        Prognostic factors for the outcome of nonfunctioning pancreatic neuroendocrine tumors in MEN1: a systematic review of literature.
        Endocr Relat Cancer. 2020; 27: R145-R161
        • de Rooij T.
        • van Hilst J.
        • van Santvoort H.
        • et al.
        Minimally invasive versus open distal pancreatectomy (LEOPARD): a multicenter patient-blinded randomized controlled trial.
        Ann Surg. 2019; 269: 2-9
        • van Hilst J.
        • de Rooij T.
        • Bosscha K.
        • et al.
        Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient-blinded, randomised controlled phase 2/3 trial.
        Lancet Gastroenterol Hepatol. 2019; 4: 199-207
        • Boone B.A.
        • Zenati M.
        • Hogg M.E.
        • et al.
        Assessment of quality outcomes for robotic pancreaticoduodenectomy: identification of the learning curve.
        JAMA Surg. 2015; 150: 416-422
        • Ricci C.
        • Casadei R.
        • Taffurelli G.
        • et al.
        Minimally Invasive Pancreaticoduodenectomy: What is the Best “Choice”? A Systematic Review and Network Meta-analysis of Non-randomized Comparative Studies.
        World J Surg. 2018; 42: 788-805
        • Huttner F.J.
        • Koessler-Ebbs J.
        • Hackert T.
        • et al.
        Meta-analysis of surgical outcome after enucleation versus standard resection for pancreatic neoplasms.
        Br J Surg. 2015; 102: 1026-1036
        • Dragomir M.P.
        • Sabo A.A.
        • Petrescu G.E.D.
        • et al.
        Central pancreatectomy: a comprehensive, up-to-date meta-analysis.
        Langenbecks Arch Surg. 2019; 404: 945-958
        • Dalla Valle R.
        • Cremaschi E.
        • Lamecchi L.
        • et al.
        Open and minimally invasive pancreatic neoplasms enucleation: a systematic review.
        Surg Endosc. 2019; 33: 3192-3199
        • Wakabayashi T.
        • Felli E.
        • Cherkaoui Z.
        • et al.
        Robotic Central Pancreatectomy for Well-Differentiated Neuroendocrine Tumor: Parenchymal-Sparing Procedure.
        Ann Surg Oncol. 2019; 26: 2121
        • Keutgen X.M.
        • Nilubol N.
        • Glanville J.
        • et al.
        Resection of primary tumor site is associated with prolonged survival in metastatic nonfunctioning pancreatic neuroendocrine tumors.
        Surgery. 2016; 159: 311-318
        • Dasari A.
        • Mehta K.
        • Byers L.A.
        • et al.
        Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases.
        Cancer. 2018; 124: 807-815
        • Patel S.P.
        • Othus M.
        • Chae Y.K.
        • et al.
        A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors.
        Clin Cancer Res. 2020; 26: 2290-2296
        • Bagante F.
        • Spolverato G.
        • Merath K.
        • et al.
        Neuroendocrine liver metastasis: The chance to be cured after liver surgery.
        J Surg Oncol. 2017; 115: 687-695
        • Graff-Baker A.N.
        • Sauer D.A.
        • Pommier S.J.
        • et al.
        Expanded criteria for carcinoid liver debulking: maintaining survival and increasing the number of eligible patients.
        Surgery. 2014; 156 ([discussion: 1376-7]): 1369-1376
        • Panzuto F.
        • Boninsegna L.
        • Fazio N.
        • et al.
        Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression.
        J Clin Oncol. 2011; 29: 2372-2377
        • Scott A.T.
        • Breheny P.J.
        • Keck K.J.
        • et al.
        Effective cytoreduction can be achieved in patients with numerous neuroendocrine tumor liver metastases (NETLMs).
        Surgery. 2019; 165: 166-175
        • Gangi A.
        • Howe J.R.
        The Landmark Series: Neuroendocrine Tumor Liver Metastases.
        Ann Surg Oncol. 2020; 27: 3270-3280
        • Morgan R.E.
        • Pommier S.J.
        • Pommier R.F.
        Expanded criteria for debulking of liver metastasis also apply to pancreatic neuroendocrine tumors.
        Surgery. 2018; 163: 218-225
        • Chen J.X.
        • Wileyto E.P.
        • Soulen M.C.
        Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver (RETNET): study protocol for a randomized controlled trial.
        Trials. 2018; 19: 390
        • Mayo S.C.
        • de Jong M.C.
        • Bloomston M.
        • et al.
        Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis.
        Ann Surg Oncol. 2011; 18: 3657-3665
        • Yao J.C.
        • Fazio N.
        • Singh S.
        • et al.
        Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study.
        J Clin Oncol. 2016; 34: 3906-3913
        • Caplin M.E.
        • Pavel M.
        • Cwikla A.
        • et al.
        Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
        N Engl J Med. 2014; 371: 224-233
        • Strosberg J.
        • El-Haddad G.
        • Wolin E.
        • et al.
        Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors.
        N Engl J Med. 2017; 376: 125-135
        • Rinke A.
        • Wittenberg M.
        • Schade-Brittinger C.
        • et al.
        Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival.
        Neuroendocrinology. 2017; 104: 26-32
        • Kaderli R.M.
        • Spanjol M.
        • Kollar A.
        • et al.
        Therapeutic options for neuroendocrine tumors: a systematic review and network meta-analysis.
        JAMA Oncol. 2019; 5: 480-489
        • Rinke A.
        • Muller H.H.
        • Schade-Brittinger C.
        • et al.
        Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.
        J Clin Oncol. 2009; 27: 4656-4663
        • Yao J.C.
        • Fazio N.
        • Singh S.
        • et al.
        Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.
        Lancet. 2016; 387: 968-977
        • Raymond E.
        • Dahan L.
        • Raoul J.L.
        • et al.
        Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
        N Engl J Med. 2011; 364: 501-513
        • Kunz P.L.
        • Catalano P.J.
        • Nimeiri H.
        • et al.
        A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211).
        J Clin Oncol. 2018; 36: 4004